Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 20

Results For "NIV"

815 News Found

Schneider Electric launches EcoStruxure for life science segment
Sustainability | June 11, 2024

Schneider Electric launches EcoStruxure for life science segment

Accelerating sustainability in Indian pharma industry


Abbott wins CE mark for dual-chamber leadless pacemaker
News | June 11, 2024

Abbott wins CE mark for dual-chamber leadless pacemaker

Abbott's first-of-its-kind i2i technology enables synchronized communication between two leadless pacemakers


Melissa Seymour to join Lilly as executive vice president of Global Quality
People | June 06, 2024

Melissa Seymour to join Lilly as executive vice president of Global Quality

Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry


Melissa Seymour to join Lilly as executive vice president of Global Quality
People | June 06, 2024

Melissa Seymour to join Lilly as executive vice president of Global Quality

Seymour is recognized as one of the foremost quality leaders in the pharmaceutical industry


Bristol Myers Squibb announces Opdivo Plus Yervoy (ipilimumab) improved overall survival for patients with unresectable hepatocellular carcinoma
Diagnostic Center | June 05, 2024

Bristol Myers Squibb announces Opdivo Plus Yervoy (ipilimumab) improved overall survival for patients with unresectable hepatocellular carcinoma

Dual immunotherapy combination of Opdivo plus Yervoy demonstrated improved survival benefit compared to lenvatinib or sorafenib in this patient population


Pfizer’s ADCETRIS regimen produces clinically meaningful improvement in overall survival in patients with DLBCL
Diagnostic Center | June 04, 2024

Pfizer’s ADCETRIS regimen produces clinically meaningful improvement in overall survival in patients with DLBCL

Third Phase 3 trial in third type of lymphoma to show improvement in overall survival with an ADCETRIS-containing regimen


Takeda and Pfizer announce results from Positive Phase 3 HD21 trial of additional ADCETRIS combination in frontline hodgkin lymphoma
News | June 03, 2024

Takeda and Pfizer announce results from Positive Phase 3 HD21 trial of additional ADCETRIS combination in frontline hodgkin lymphoma

The HD21 study adds to the body of evidence supporting ADCETRIS as a backbone agent in the treatment of specific lymphomas


AbbVie receives positive CHMP opinion for Risankizumab for treatment ulcerative colitis
News | June 01, 2024

AbbVie receives positive CHMP opinion for Risankizumab for treatment ulcerative colitis

Ulcerative Colitis (UC) is a chronic, idiopathic, immune-mediated inflammatory bowel disease (IBD) affecting the large intestine


Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction
Diagnostic Center | May 27, 2024

Novartis atrasentan Phase III data show clinically meaningful proteinuria reduction

Through its rare kidney disease portfolio, Novartis is committed to exploring a range of treatment options with different modes of action to slow IgAN progression


Dupixent late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM
Diagnostic Center | May 21, 2024

Dupixent late-breaking data from NOTUS confirmatory phase 3 COPD study presented at ATS and published in NEJM

Data support the potential of Dupixent as the first new treatment approach in more than a decade and first-ever targeted therapy for COPD